secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037574
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO
--------------------------------------------------------------------------------

- Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.
- Screening closed for Phase 3 REACH trial of losmapimod in FSHD; topline data expected Q4 2024.
- Alan A. Musso appointed CFO effective Aug 7, 2023; base salary $450K, 40% target bonus, 432,800 stock option.
- Licensed global rights from CAMP4 for Diamond-Blackfan Anemia; clinical hold for FTX-6058 remains unresolved.
- R&D expenses fell to $17.8M from $25.0M YoY; cash runway into mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/fulc-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer